Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
54.44
+0.76 (1.42%)
At close: Jun 25, 2025, 4:00 PM
54.61
+0.17 (0.31%)
After-hours: Jun 25, 2025, 6:19 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $67.11, which forecasts a 23.27% increase in the stock price over the next year. The lowest target is $51 and the highest is $80.
Price Target: $67.11 (+23.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citigroup | Citigroup | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +32.26% | Jun 17, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +46.95% | Jun 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +46.95% | May 19, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +46.95% | Apr 10, 2025 |
Wedbush | Wedbush | Buy Reiterates $70 | Buy | Reiterates | $70 | +28.58% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
83.56M
from 434.43M
Decreased by -80.77%
Revenue Next Year
122.95M
from 83.56M
Increased by 47.15%
EPS This Year
-1.98
from 4.23
EPS Next Year
-1.83
from -1.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 266.1M | 302.4M | 711.9M | ||
Avg | 83.6M | 123.0M | 218.3M | ||
Low | 27.7M | 19.6M | 46.1M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -38.8% | 261.9% | 479.0% | ||
Avg | -80.8% | 47.1% | 77.5% | ||
Low | -93.6% | -76.5% | -62.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.23 | -0.58 | -0.17 | ||
Avg | -1.98 | -1.83 | -1.13 | ||
Low | -2.47 | -3.64 | -2.18 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.